BioSpace News Archive

Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces that Mr. Donald McInnes has resigned as a director of the Company, effective immediately, so that he can focus his efforts on other professional commitments.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates targeting diseases with high unmet medical need and leading the clinical development of cannabinol (“CBN”), today announced that Eric A. Adams, President and CEO of InMed, will be presenting at investor conferences in March 2021.

Owens & Minor, Inc. announced the pricing of its private offering of $500 million aggregate principal amount of its 4.500% senior notes due 2029.

DURECT Corporation (Nasdaq: DRRX) today announced that it will partipate in three upcoming investor conferences, taking place in March 2021. All conferences will take place virtually.

On HPV Awareness Day, the International Papillomavirus Society is urging women to attend delayed cervical screenings and for all interrupted services to re-start as thousands continue to miss out on vital HPV care, with deadly consequences.

Heal, the pioneer of in-home primary care, today announces the appointment of Scott Vertrees as chief executive officer.

InnovAge Holding Corp. (InnovAge) today announced the pricing of its initial public offering of 16,666,667 shares of its common stock at a price to the public of $21.00 per share. The shares are expected to begin trading on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol “INNV” on March 4, 2021,

The U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s (NYSE: PFE) supplemental New Drug Application (sNDA) for LORBRENA® (lorlatinib), expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

The acquisition brings behavioral science, AI, and virtual care enhancements to the BioIQ digital health testing platform.

Grant Will Provide Bridge Funding for Dr. H Lee Sweeney’s Research to Understand and Improve Gene Therapy in Duchenne